Market Research Logo

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018

Introduction
Global Markets Direct Report Coverage
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Actuate Therapeutics Inc
AMO Pharma Ltd
Angelini Group
Jeil Pharmaceutical Co Ltd
Mitsubishi Tanabe Pharma Corp
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
9-ING41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-AD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JGK-263 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
manzamine A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GSK3B for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK-3 Beta for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK3B for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tideglusib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers
Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma
Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study
Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy
May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research
Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy
Mar 29, 2016: FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma
Dec 18, 2015: Actuate Therapeutics Provides Update On 9-ING4
Nov 19, 2015: Actuate Therapeutics Presents Data On 9-ING41 at the Society of Neuro Oncology meeting
Apr 20, 2015: Actuate Therapeutics Provides Update On GSK-3B at the AACR Meeting
Dec 03, 2012: Alzheimer's researcher reveals a protein's dual destructiveness - and therapeutic potential
Jul 20, 2012: Noscira Presents Phase II Results Of tideglusib At Alzheimer's Association International Conference 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Actuate Therapeutics Inc, H1 2018
Pipeline by AMO Pharma Ltd, H1 2018
Pipeline by Angelini Group, H1 2018
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

The latest report Glycogen Synthase Kinase 3 Beta - Pipeline Review, H1 2018, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules.

It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex.

It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Alzheimer's Disease, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Lung Cancer, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Menkes Disease (Kinky Hair Disease), Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Retinitis Pigmentosa (Retinitis) and Tauopathies.

Furthermore, this report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;